A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
The National Cholesterol Education Program recognizes the importance of the metabolic syndrome and has published guidelines for its diagnosis. Weight loss, physical activity, and treatment of the individual risk factors constitute the main strategies for treatment. For now, the goals and methods of treating hypertension and dyslipidemia are the same in people with the metabolic syndrome as in the general population. Thiazolidinedione drugs increase insulin sensitivity, but their use in the metabolic syndrome is only speculative at present. We recommend they be used only as indicated to treat diabetes mellitus.
Nambi
Vijay
V
Department of Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA.
Hoogwerf
Byron J
BJ
Sprecher
Dennis L
DL
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006946:Hyperinsulinism / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy; D015228:Hypertriglyceridemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000628:therapy*; D008687:Metformin / Q000627:therapeutic use; D009043:Motor Activity / Q000502:physiology; D009765:Obesity / Q000628:therapy; D019821:Simvastatin / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones; D015431:Weight Loss / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D008687:Metformin; C089946:2,4-thiazolidinedione; D019821:Simvastatin